Differences in Plasma Fibrin Clot Composition in Patients with Thrombotic Antiphospholipid Syndrome Compared with Venous Thromboembolism

Overview

Journal Sci Rep

Specialty Science

Date 2018 Nov 25

PMID 30470809

Citations 10

Authors

Aneta Stachowicz

Michal Zabczyk

Joanna Natorska

Maciej Suski

Rafal Olszanecki

Ryszard Korbut

Jacek R Wisniewski

Anetta Undas

Affiliations

Soon will be listed here.

Abstract

The prothrombotic fibrin clot phenotype has been reported in patients with thrombotic antiphospholipid syndrome (APS) and venous thromboembolism (VTE). Protein composition of plasma fibrin clots in APS has not been studied. We evaluated 23 patients with thrombotic APS, 19 with VTE alone, and 20 well-matched controls. A proteomic analysis of fibrin clots generated from citrated plasma was based on liquid chromatography-mass spectrometry. Plasma levels of thrombospondin-1 (TSP1), apolipoprotein(a), A-I, and B-100, complement components (C)3a, C5b-C9, histidine-rich glycoprotein (HRG), and prothrombin were evaluated using immunoenzymatic tests. In plasma fibrin clots of APS patients, compared with VTE subjects and controls, we identified decreased amounts of (pro)thrombin, antithrombin-III, apolipoprotein A-I, and HRG with no differences in plasma levels of antithrombin, prothrombin, along with lower plasma HRG and apolipoprotein A-I. In APS patients, plasma HRG positively correlated with amounts of clot-bound HRG, while apolipoprotein A-I was inversely associated with clot-bound levels of this protein. The most predominant proteins within the clots of APS patients were bone marrow proteoglycan, C5-C9, immunoglobulins, apolipoprotein B-100, platelet-derived proteins, and TSP1. Our study is the first to demonstrate differences in the protein composition of fibrin clots generated from plasma of thrombotic APS patients versus those with VTE alone.

Citing Articles

Complement activation is associated with right ventricular dysfunction and the severity of pulmonary embolism: links with prothrombotic state.

Rostoff P, Zabczyk M, Natorska J, Undas A J Thorac Dis. 2024; 16(5):3181-3191.

PMID: 38883666 PMC: 11170391. DOI: 10.21037/jtd-24-171.

The Role of Neutrophil Extracellular Traps (NETs) in the Pathogenesis of Systemic Lupus Erythematosus and Antiphospholipid Syndrome.

Reshetnyak T, Nurbaeva K Int J Mol Sci. 2023; 24(17).

PMID: 37686381 PMC: 10487763. DOI: 10.3390/ijms241713581.

Fibrin clot properties in cardiovascular disease: from basic mechanisms to clinical practice.

Zabczyk M, Ariens R, Undas A Cardiovasc Res. 2023; 119(1):94-111.

PMID: 36662542 PMC: 10377755. DOI: 10.1093/cvr/cvad017.

Effects of Intermittent Fasting in Human Compared to a Non-intervention Diet and Caloric Restriction: A Meta-Analysis of Randomized Controlled Trials.

Gu L, Fu R, Hong J, Ni H, Yu K, Lou H Front Nutr. 2022; 9:871682.

PMID: 35586738 PMC: 9108547. DOI: 10.3389/fnut.2022.871682.

The Pathophysiology of The Antiphospholipid Syndrome: A Perspective From The Blood Coagulation System.

Arreola-Diaz R, Majluf-Cruz A, Sanchez-Torres L, Hernandez-Juarez J Clin Appl Thromb Hemost. 2022; 28:10760296221088576.

PMID: 35317658 PMC: 8950029. DOI: 10.1177/10760296221088576.

References

Lim W . Complement and the antiphospholipid syndrome. Curr Opin Hematol. 2011; 18(5):361-5. DOI: 10.1097/MOH.0b013e3283497f3e. View

Undas A, Stepien E, Tracz W, Szczeklik A . Lipoprotein(a) as a modifier of fibrin clot permeability and susceptibility to lysis. J Thromb Haemost. 2006; 4(5):973-5. DOI: 10.1111/j.1538-7836.2006.01903.x. View

Oku K, Atsumi T, Bohgaki M, Amengual O, Kataoka H, Horita T . Complement activation in patients with primary antiphospholipid syndrome. Ann Rheum Dis. 2008; 68(6):1030-5. DOI: 10.1136/ard.2008.090670. View

Yalavarthi S, Gould T, Rao A, Mazza L, Morris A, Nunez-Alvarez C . Release of neutrophil extracellular traps by neutrophils stimulated with antiphospholipid antibodies: a newly identified mechanism of thrombosis in the antiphospholipid syndrome. Arthritis Rheumatol. 2015; 67(11):2990-3003. PMC: 4626310. DOI: 10.1002/art.39247. View

Vu T, Stafford A, Leslie B, Kim P, Fredenburgh J, Weitz J . Histidine-rich glycoprotein binds fibrin(ogen) with high affinity and competes with thrombin for binding to the gamma'-chain. J Biol Chem. 2011; 286(35):30314-30323. PMC: 3162390. DOI: 10.1074/jbc.M111.253831. View

Otomo K, Amengual O, Fujieda Y, Nakagawa H, Kato M, Oku K . Role of apolipoprotein B100 and oxidized low-density lipoprotein in the monocyte tissue factor induction mediated by anti-β2 glycoprotein I antibodies. Lupus. 2016; 25(12):1288-98. DOI: 10.1177/0961203316638165. View

Nikolajsen C, Dyrlund T, Poulsen E, Enghild J, Scavenius C . Coagulation factor XIIIa substrates in human plasma: identification and incorporation into the clot. J Biol Chem. 2014; 289(10):6526-6534. PMC: 3945317. DOI: 10.1074/jbc.M113.517904. View

Iwaniec T, Kaczor M, Celinska-Lowenhoff M, Polanski S, Musial J . Identification of patients with triple antiphospholipid antibody positivity is platform and method independent. Pol Arch Med Wewn. 2016; 126(1-2):19-24. DOI: 10.20452/pamw.3259. View

Allan P, Uitte de Willige S, Abou-Saleh R, Connell S, Ariens R . Evidence that fibrinogen γ' directly interferes with protofibril growth: implications for fibrin structure and clot stiffness. J Thromb Haemost. 2012; 10(6):1072-80. DOI: 10.1111/j.1538-7836.2012.04717.x. View

10.

Vizcaino J, Csordas A, Del-Toro N, Dianes J, Griss J, Lavidas I . 2016 update of the PRIDE database and its related tools. Nucleic Acids Res. 2015; 44(D1):D447-56. PMC: 4702828. DOI: 10.1093/nar/gkv1145. View

11.

Wisniewski J, Mann M . Consecutive proteolytic digestion in an enzyme reactor increases depth of proteomic and phosphoproteomic analysis. Anal Chem. 2012; 84(6):2631-7. DOI: 10.1021/ac300006b. View

12.

Zabczyk M, Blomback M, Majewski J, Karkowski G, Wallen H, Undas A . Assays of fibrin network properties altered by VKAs in atrial fibrillation - importance of using an appropriate coagulation trigger. Thromb Haemost. 2014; 113(4):851-61. DOI: 10.1160/TH14-07-0591. View

13.

Talens S, Leebeek F, Demmers J, Rijken D . Identification of fibrin clot-bound plasma proteins. PLoS One. 2012; 7(8):e41966. PMC: 3411686. DOI: 10.1371/journal.pone.0041966. View

14.

Peerschke E, Yin W, Ghebrehiwet B . Complement activation on platelets: implications for vascular inflammation and thrombosis. Mol Immunol. 2010; 47(13):2170-5. PMC: 2904326. DOI: 10.1016/j.molimm.2010.05.009. View

15.

Celinska-Lowenhoff M, Zabczyk M, Iwaniec T, Plens K, Musial J, Undas A . Reduced plasma fibrin clot permeability is associated with recurrent thromboembolic events in patients with antiphospholipid syndrome. Rheumatology (Oxford). 2018; 57(8):1340-1349. DOI: 10.1093/rheumatology/key089. View

16.

Lacroix R, Dubois C, Leroyer A, Sabatier F, Dignat-George F . Revisited role of microparticles in arterial and venous thrombosis. J Thromb Haemost. 2013; 11 Suppl 1:24-35. DOI: 10.1111/jth.12268. View

17.

Cox J, Hein M, Luber C, Paron I, Nagaraj N, Mann M . Accurate proteome-wide label-free quantification by delayed normalization and maximal peptide ratio extraction, termed MaxLFQ. Mol Cell Proteomics. 2014; 13(9):2513-26. PMC: 4159666. DOI: 10.1074/mcp.M113.031591. View

18.

Rand J, Wu X, Wolgast L, Lei V, Conway E . A novel 2-stage approach that detects complement activation in patients with antiphospholipid antibody syndrome. Thromb Res. 2017; 156:119-125. DOI: 10.1016/j.thromres.2017.06.014. View

19.

Vikerfors A, Svenungsson E, Agren A, Mobarrez F, Bremme K, Holmstrom M . Studies of fibrin formation and fibrinolytic function in patients with the antiphospholipid syndrome. Thromb Res. 2014; 133(5):936-44. DOI: 10.1016/j.thromres.2014.02.023. View

20.

Shi T, Giannakopoulos B, Yan X, Yu P, Berndt M, Andrews R . Anti-beta2-glycoprotein I antibodies in complex with beta2-glycoprotein I can activate platelets in a dysregulated manner via glycoprotein Ib-IX-V. Arthritis Rheum. 2006; 54(8):2558-67. DOI: 10.1002/art.21968. View